111 results about "Fat accumulation" patented technology

The present invention provides a method for inducing fat accumulation in a cell of a fish, including contacting a cell obtained or derived from a fish with an effective amount of a composition including: (i) a fat accumulation inducing agent; and (ii) a carrier, wherein the fat accumulation inducing agent consists essentially of a free fatty acid and a peroxisome proliferator-activated receptor gamma (PPARy) agonist. Further provided are a cultured fish cell including an increased amount of a PUFA and a reduced amount of MUFA, compared to a control fish cell, and an edible composition including the same.

The invention relates to a lactobacillus rhamnosus YYSJ019 strain for relieving obesity and application of the lactobacillus rhamnosus YYSJ019 strain. The lactobacillus rhamnosus YYSJ019 strain is classified and named as lactobacillus rhamnosus, and the preservation number of the lactobacillus rhamnosus YYSJ019 strain is CGMCC (China General Microbiological Culture Collection Center) No.33472. The strain has good tolerance and high surface hydrophobicity in gastric juice, and has the potential of smoothly entering the gastrointestinal tract of a human body; the bacterial strain has excellent intestinal adhesion capability, and provides a basis for continuously playing a probiotic effect; the strain can slow down weight gain of obese mice and improve fat accumulation, liver injury and inflammation in bodies of the obese mice; the blood sugar metabolism capability and the blood fat metabolism capability can also be improved, and the potential of preventing and treating hyperglycemia or hyperlipidemia is achieved; in addition, a mouse small intestine endocrine cell line (STC-1 cell line) can be stimulated to generate the glucagon-like peptide-1, and the glucagon-like peptide-1 has the potential of improving diseases caused by insufficient secretion of the glucagon-like peptide-1; the effects of reducing uric acid in vitro and reducing uric acid in vivo are achieved, and the potential of preventing and treating hyperuricemia is achieved.

The invention belongs to the field of food processing, and particularly relates to rice starch ester as well as a preparation method and application thereof. According to the invention, by exploring the action rule of reaction time, reaction temperature, pH value and acid addition amount on modified rice starch ester, the content of resistant starch in rice starch is increased and the GI value is reduced through esterification modification, so that the rice starch with the function of regulating blood sugar level is obtained; the product also can significantly improve inflammation and fat accumulation symptoms caused by hyperglycemia; in a diet intervention experiment, both the CRS and the MRS show an effective reduction effect on the weight growth rate, the blood sugar level, the visceral organ index and the inflammatory factor content of the hyperglycemia mouse. The result shows that the CA / MA rice starch ester not only has the function of regulating the blood sugar level, but also can remarkably improve inflammation and fat accumulation symptoms caused by hyperglycemia, and has a positive effect on maintaining the overall health.

Provided is a novel Lactobacillus fermentum strain (Accession No. KCTC 14106BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus fermentum according to the present invention may inhibit fat accumulation and increase anti-inflammatory cells in white adipose tissue. In addition, the Lactobacillus fermentum may effectively inhibit fat accumulation in brown adipose tissue and in liver tissue. The Lactobacillus fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. Therefore, the Lactobacillus fermentum strain may be usefully used to prevent or treat a metabolic disease such as obesity.

The present invention relates to the application of saliva combined with lactobacillus in the preparation of a drug for treating obesity, and belongs to the field of biomedicine technology. The present invention provides the application of saliva combined with lactobacillus XA-1416 in the preparation of a drug for preventing and / or treating obesity, or preventing and / or treating obesity-related diseases. This strain can inhibit the weight gain of mice with obesity model induced by high-fat diet, reduce the blood lipid level of mice with obesity model induced by high-fat diet, improve the liver damage index of mice with obesity model induced by high-fat diet, reduce the area of ​​white fat cells in mice with obesity model induced by high-fat diet, promote the conversion of intestinal conjugated bile acid to free bile acid in mice with obesity model induced by high-fat diet, increase the level of intestinal FXR antagonist in mice with obesity model induced by high-fat diet, improve the intestinal flora imbalance of mice with obesity model induced by high-fat diet, inhibit fat accumulation in Hep G2 model, and inhibit differentiation into adipocytes in 3T3-L1 model.

The invention provides isolated Ackermania muciniphila, a composition containing the same and application of the Ackermania muciniphila in preventing re-fatting. According to the present invention, the Akkermansia muciniphila has characteristics of high automatic aggregation ability and strong surface hydrophobicity, can effectively adhere to the intestinal epithelial cells, can prolong the intestinal retention time, and can improve the treatment effect. The strain adapts to the intestinal environment and is high in stability. The Akkermansia muciniphila disclosed by the invention can be used for remarkably inhibiting body weight rebound (reducing body weight growth rate and fat accumulation) after drug withdrawal, improving blood sugar steady state (reducing postprandial blood sugar and fasting blood sugar) and reducing visceral fat accumulation, and the action is lasting and does not rebound. An efficient and safe microbial therapy solution is provided for maintaining the body weight and preventing an easily-fat object from developing obesity after obesity treatment.

The invention provides an application of liquiritin in preparation of a PPAR gamma receptor partial agonist. Through a structure-based high-throughput virtual screening technology, it is found that liquiritin can be used as a partial agonist of a PPAR gamma receptor, and the relative activation efficiency of liquiritin is 35.9% of that of rosiglitazone; in-vitro experiments prove that liquiritin can remarkably promote glucose uptake and consumption of HepG2 cells and does not induce adipocyte differentiation; in-vivo experiments prove that liquiritin can effectively improve the blood glucose level of an insulin resistance mouse model induced by high fat diet and reduce the level of serum proinflammatory factors. Compared with thiazolidinedione compounds, liquiritin not only can relieve and treat insulin resistance or related metabolic diseases, but also does not cause adverse reactions such as weight gain, fat accumulation and myocardial hypertrophy, provides a new candidate compound for developing safe and effective anti-diabetic drugs, and has a wide application prospect.

The invention belongs to the technical field of traditional Chinese medicine research, and particularly relates to ganoderma lucidum polysaccharide and an extraction method and application thereof. The structural formula of the ganoderan is shown as a formula I in the specification. The ganoderan extracted by the invention can repair intestinal barriers by promoting the growth of beneficial intestinal bacteria, alleviate liver inflammation by targeting LPS / TLR4 / NF-kappa B / MAPK signal pathways, and reduce fat accumulation, thereby effectively alleviating the non-alcoholic fatty liver disease; and # imgabs0 #.

The application discloses a construction method of a fat-targeted gene therapy vector. The method comprises the following steps: obtaining a fat tissue-specific promoter sequence; obtaining a shRNA coding sequence targeting a Tks4 gene; cloning the promoter sequence and the shRNA coding sequence into an adeno-associated virus vector skeleton to construct a recombinant expression vector; and co-transfecting the recombinant expression vector and an auxiliary plasmid into a packaging cell to package and purify a recombinant adeno-associated virus particle. The vector constructed by the application adopts an adiponectin promoter to drive the expression of miR30-shRNA targeting the Tks4, and can be specifically expressed in fat tissues and livers after being injected through a tail vein, significantly inhibits fat cell hypertrophy and systemic fat accumulation induced by a high-fat diet, reduces the serum cholesterol level, does not cause an immune inflammatory reaction, does not affect sugar metabolism, and is not expressed in non-target tissues. The application provides a safe and efficient new strategy for the gene therapy of obesity, hyperlipidemia, fatty liver and related metabolic diseases.

The present invention addresses the problem of defining physiological significance and functions such as the influence of nicotinamide mononucleotide (NMN) contained in breast milk on the development of children. A composition for improving the athletic ability of a child is provided comprising a precursor of NAD. The improvement in athletic ability is preferably any one selected from the group consisting of promotion of skeletal muscle development and improvement in activity. A composition for reducing triglyceride levels in the blood of a child is provided comprising a precursor of NAD. A composition for reducing the blood glucose level in a child is provided comprising a precursor of NAD. A composition for inhibiting fat accumulation in children is provided, comprising a precursor of NAD.

The invention discloses a pediococcus pentosaceus MDL511, which is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.35201, the preservation date is July 11, 2025, and the classification name of the strain is pediococcus pentosaceus. The pediococcus pentosaceus MDL511 has the advantages that the preservation number is CGMCC No.35201, the preservation number is CGMCC No.35201, the preservation date is July 11, 2025, and the classification name of the strain is pediococcus pentosaceus. The pediococcus pentosaceus MDL511 disclosed by the invention can be used for remarkably reducing weight gain and fat growth of mice caused by high fat diet, reducing serum cholesterol, LDL-C (Low Density Lipoprotein Cholesterol) and ALT (Atomic Lymphocyte Transferase) levels and remarkably improving hepatic lesions and fat accumulation caused by high fat diet, so that the MDL511 has a blood fat reducing effect, can be used for preparing blood fat reducing products and weight losing products and has a good development prospect.

The present invention belongs to the field of biomedical technology, and specifically relates to the application of an antifreeze protein in weight loss and blood glucose reduction. The present invention successfully constructs an NPAFP transgenic mouse model by using genetic engineering technology, and verifies the potential application value of the NPAFP protein in weight loss and blood glucose reduction. Further, based on this model, it is found that the NPAFP protein has a significant effect on reducing fat accumulation and improving blood glucose levels by regulating brown fat metabolism and liver lipid droplet content. The development of compounds or protein engineering modification based on the NPAFP protein of the present invention can provide new drugs and strategies for the treatment of obesity and diabetes. At the same time, further exploring the molecular mechanism of the NPAFP protein by combining multi-omics technologies helps to promote its clinical translation and application.

The invention aims to provide a peptide for accelerating fat metabolism and application thereof, the peptide is prepared into a product convenient to use, and the amino acid sequence of the peptide is MVHSYSETSD. The peptide is obtained through peptide library screening, bioinformatics analysis screening and fat cell decomposition experiment verification, and it is verified that the active peptide obtained through screening has the effects of accelerating fat metabolism, inhibiting fat accumulation, reducing blood fat and body fat content and reducing body weight; the insulin sensitivity and the glucose tolerance are improved, and the prevention and treatment effects on obesity and complications thereof are realized.

The present invention discloses the use of Bifidobacterium lactis MN-Gup in the preparation of dairy products for preventing or alleviating obesity or weight gain; the MN-Gup has been deposited in the General Microbiology Center of China Microbiological Culture Collection Administration, and its deposit number is CGMCC No. 15578. The present invention has the following mechanism of action: targeted improvement and regulation of obesity-characteristic intestinal flora, increasing the abundance of beneficial bacteria related to obesity, reducing the abundance of harmful bacteria related to obesity, improving and restoring the health of intestinal flora; inhibiting inflammatory factors IL-1β, TNF-α, IL-6 and INF-γ, improving obesity-related inflammatory response; reducing triglycerides, cholesterol and / or low-density lipoprotein, increasing high-density lipoprotein, achieving the goal of reducing blood lipids and inhibiting fat accumulation; inhibiting adipose tissue degeneration; and comprehensively preventing, alleviating or improving obesity or weight gain through the above mechanism.

The application aims to provide a peptide for accelerating fat metabolism and application thereof, and to prepare the peptide into a product convenient to use, and the amino acid sequence of the peptide is MVHSYSETSD. The peptide is obtained through screening of a peptide library, screening through bioinformatics analysis, and verification through fat cell decomposition experiment, and the application verifies that the active peptide screened has the effect of accelerating fat metabolism, inhibiting fat accumulation, reducing blood fat and body fat content, reducing body weight, improving insulin sensitivity and glucose tolerance, and realizing the prevention and treatment effect on obesity and its complications.

The present invention provides a composition for alleviating fatty liver disease by using a single or complex extract of Sigesbeckia glabrescens and Luffa cylindrica, the composition exhibiting the activities of inhibiting fat accumulation and inflammation in liver cells without showing toxicity to liver cells, inhibiting fat accumulation and inflammation in liver tissue in high-fat-diet animal models, and increasing the expression of glutathione, which is a strong antioxidant in liver tissue.

The invention relates to the technical field of medicines, in particular to application of an integrin beta3 inhibitor RGDfK in preparation of a medicine for treating metabolic dysfunction related fatty liver diseases. The RGDfK provided by the invention can inhibit palmitoylation and membrane localization of CD36 in liver tissues of mice with fatty liver diseases related to metabolic dysfunction induced by high fat diet feeding, so that lipid uptake of the liver is inhibited. Experimental results show that RGDfK can improve obesity and insulin resistance of mice with metabolic dysfunction-related fatty liver diseases, can improve fat accumulation, fibrosis and inflammatory infiltration of liver tissues of the mice with fatty liver diseases, and is expected to become a new medicine for treating the metabolic dysfunction-related fatty liver diseases.

Disclosed is use of a polypeptide in the preparation of drugs, foods, or health care products for treating obesity and comorbidities thereof, which belongs to the technical field of biological medicines. The polypeptide is a human GPR15L polypeptide or a mouse GPR15L polypeptide and a polypeptide conjugate thereof. The treatment of obesity includes: reducing fat accumulation, promoting fat thermogenesis and catabolism, increasing energy consumption, and reducing body weight. The obesity comorbidities include: chronic inflammation, fatty liver, steatohepatitis, metabolic diseases, cardiovascular and cerebrovascular diseases, osteoarticular diseases, Alzheimer's disease, depression, tumors, and skin diseases. A novel mechanism of action reduces blood glucose and body weight, thereby effectively treating obesity and comorbidities thereof.

1. The name of the design product: anti-fat accumulation instrument. 2. The use of the design product: the design product is used for cosmetic instrument of massage, anti-fat accumulation and anti-wrinkle treatment. 3. The design points of the design product: in shape. 4. The picture or photo that can best show the design points: perspective view.

Described herein is a novel, mitochondrial encoded, open reading frame, that leads to the production of a new mitochondrial peptide. Residing within the ND-Two subunit, a specific small nucleotide polymorphism disrupts expression of this mitochondrial peptide, and is correlated with an increase in obesity and diabetes, particularly in certain ethnic populations. In vitro administration of the peptide increases insulin secretion, decreases fat accumulation and improves glucose uptake in muscle cell. Antibodies generated against the peptide can be used for detecting peptide deficiency, in addition to SNP detection, supporting diagnostic approaches. In vivo studies further revealed that administration of the peptide improves glucose tolerance, thereby providing a new therapeutic avenue for a novel diabetes therapy and decreases bodyweight, thus serving as a novel obesity therapy. Generation of synthetic analogs further enhance or abrogated activity relative to the natural peptide.

The present invention relates to a peptide complex having activities of preventing or treating fatty liver disease. The peptide complex of the present invention inhibits, in hepatocytes, the expression of fat synthesis-related genes and proteins and promotes the expression of fatty acid oxidation-related genes and proteins, and thus can inhibit, in hepatocytes, fat accumulation and promote lipolysis. In addition, the peptide complex of the present invention can inhibit the expression of inflammation-related genes in hepatocytes, and inhibits the expression of hepatotoxicity-related proteins, thereby having hepatoprotective activity. Furthermore, the peptide complex of the present invention can inhibit the degree of fat accumulation and liver fibrosis in liver tissue. Therefore, the peptide complex of the present invention is expected to be effectively used for preventing, alleviating or treating fatty liver disease.

The present invention discloses Parabacteroides distasonis NSP007 for alleviating insulin resistance and its application, belonging to the field of microbial technology. Parabacteroides distasonis NSP007 of the present invention can inhibit the weight gain and body fat accumulation of IR mice without affecting food intake; improve the glucose tolerance and insulin sensitivity of IR mice, while reducing the serum insulin and insulin resistance index of mice; regulate the lipid metabolism disorder of IR mice and relieve liver tissue damage; improve the intestinal barrier function of IR mice. The Parabacteroides distasonis NSP007 of the present invention is used for preparing a pharmaceutical composition for alleviating IR, and has very broad application prospects.

The invention provides a facial mask for promoting facial contour compactness, and relates to the technical field of cosmetic facial mask processing, the facial mask comprises clay, hyaluronic acid, collagen, vitamin C, L-carnitine, a herbal extract, dipotassium glycyrrhizinate, a humectant, a thickener, plant essential oil, nanoparticles, a green tea extract and the balance of water; the mask is prepared from the following components in parts by weight: 5-15 parts of clay, 1-3 parts of hyaluronic acid, 3-6 parts of collagen, 1-3 parts of vitamin C, 1-10 parts of L-carnitine, 10-18 parts of herbal extract, 1-2 parts of dimethyl glycyrrhizinate, 2-5 parts of humectant, 2-5 parts of thickener, 1-3 parts of plant essential oil, 3-8 parts of nanoparticles, 1-4 parts of green tea extract and the balance of deionized water. On one hand, the mask can tighten the skin, brighten the skin color and achieve the functions of preserving heat, nourishing, tightening the contour and preventing fat accumulation, and on the other hand, the nano-particles are added, so that active ingredients in the mask can be more uniformly distributed on the skin, and the acting effect of the mask is fully improved.

This document describes the crystalline and liquid crystalline forms of sodium 25HC3S. This disclosure includes sodium 25HC3S in forms I, II, III, V, IX, XI, and XIII, and combinations thereof. Pharmaceutical formulations of the said forms or combinations thereof are further disclosed herein, as well as methods for treating or preventing diseases such as hypercholesterolemia, hypertriglyceridemia, and conditions associated with fat accumulation and inflammation (e.g., non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, and atherosclerosis). Methods for preparing 25HC3S are also provided.

The invention discloses an application of an MEN1 gene and an encoded protein thereof in preparation of a medicine for preventing or treating obesity and metabolic complications thereof, and belongs to the technical field of biology. In order to overcome the defect that in the prior art, technical gaps exist in the action of an MEN1 gene and Menin protein coded by the MEN1 gene in small intestine lipid metabolism, the invention provides application of the MEN1 gene and protein coded by the MEN1 gene in preparation of drugs for preventing or treating obesity and metabolic complications thereof, and the MEN1 gene and the coded protein Menin serve as drug targets; by down-regulating MEN1 gene expression or inhibiting Menin protein functions, fat entering blood is reduced, and obesity and metabolic disorder are improved. Therefore, the invention provides the medicine for reducing intestinal lipid entering blood, blocking excessive fat accumulation and improving insulin resistance, the HFD-induced obesity and metabolic disorder can be effectively relieved, and a novel therapeutic molecule is provided for preventing and treating obesity and complications thereof.

A biological function regulating agent comprises a fermented collagen peptide, and the fermented collagen peptide has at least one action selected from the group consisting of an epidermal metabolism promoting action, a fat accumulation inhibiting action, a fat decomposition promoting action and an action of regulating the amount of adipocytokine in a biological body.

To provide a composition useful for reducing localized fat in a subject having localized fat deposits, without pain, edema, or side effects.SOLUTION: A composition for localized fat reduction with reduced pain and side effects, comprising: (i) phosphatidylcholine; and (ii) at least one selected from a group consisting of glycocholic acid (GCA), taurocholic acid (TCA), and salts thereof, wherein (i) and (ii) have a molar ratio of (ii) / (i) of 0.7 to 3.0, and wherein the composition is administered to an affected area of a subject at intervals of less than 4 weeks at a concentration of 25 to 50 mg / ml. The composition according to the present invention provides a safe and stable formulation, is highly effective in reducing fat cells without various side effects, and can maximize its effects by being administered to the affected area at shorter intervals.SELECTED DRAWING: Figure 3

The invention belongs to the technical field of bioengineering, and particularly relates to a UBA6-C active polypeptide fragment, a recombinant vector and medical application of the UBA6-C active polypeptide fragment. The amino acid sequence of the UBA6-C active polypeptide fragment is as shown in SEQ ID NO: 1, and the nucleotide sequence of the nucleic acid molecule for coding the UBA6-C active polypeptide fragment is as shown in SEQ ID NO: 2. According to the present invention, the FAT10 loading capacity of UBA6-mediated UBE2Z is blocked by UBA6-C, the FAT10 modification is inhibited, the saturated fatty acid-induced liver cell fat accumulation is reduced, and the cell biology level proves that the UBA6-C active polypeptide has the potential MASLD alleviation or treatment effect;

The present invention relates to a composition for alleviating obesity or improving lipid metabolism, comprising a Rostellularia procumbens extract. The Rostellularia procumbens extract according to the present invention has the effects of inhibiting weight gain and fat accumulation and lowering blood levels of total triglycerides, total cholesterol, and low-density lipoprotein. In addition, the Rostellularia procumbens extract of the present invention, as a natural medicinal agent, can be applied to various products such as pharmaceutical compositions, food compositions, and feed compositions for the prevention, treatment, or alleviation of obesity or for the improvement of lipid metabolism.